Neurocrine Biosciences (NASDAQ: NBIX) and Compugen (NASDAQ:CGEN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership and risk.
Volatility and Risk
Neurocrine Biosciences has a beta of 0.34, indicating that its stock price is 66% less volatile than the S&P 500. Comparatively, Compugen has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500.
This table compares Neurocrine Biosciences and Compugen’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Insider & Institutional Ownership
21.2% of Compugen shares are owned by institutional investors. 4.3% of Neurocrine Biosciences shares are owned by company insiders. Comparatively, 9.5% of Compugen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This is a summary of recent ratings and recommmendations for Neurocrine Biosciences and Compugen, as reported by MarketBeat.
||Strong Buy Ratings
Neurocrine Biosciences currently has a consensus price target of $104.62, indicating a potential upside of 0.07%. Compugen has a consensus price target of $9.00, indicating a potential upside of 176.92%. Given Compugen’s higher possible upside, analysts plainly believe Compugen is more favorable than Neurocrine Biosciences.
Earnings and Valuation
This table compares Neurocrine Biosciences and Compugen’s gross revenue, earnings per share and valuation.
||Earnings Per Share
Compugen has lower revenue, but higher earnings than Neurocrine Biosciences. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.
Compugen beats Neurocrine Biosciences on 8 of the 13 factors compared between the two stocks.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease. It is also developing NBI-74788, which is in Phase II clinical trial that is used for the treatment of congenital adrenal hyperplasia. In addition, the company's research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, dystonia, and other indications. It has collaborations and agreements with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL ? Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's pipeline primarily includes early and preclinical stage immuno-oncology programs based on novel drug targets, such as immune checkpoint and myeloid protein target candidates to harness the immune system to provide treatment solutions in the areas of unmet medical needs in various cancer types and patient populations. Its antibody drug conjugate target candidates comprise CGEN-15001T, CGEN-15022, CGEN-15029, and CGEN-15137 for oncology; and therapeutic proteins include CGEN-15001, a fusion protein for autoimmune diseases, as well as CGEN myeloid target. The company was incorporated in 1993 and is headquartered in Holon, Israel.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.